RALEIGH, NC, July 2023, ProPharma Group (ProPharma), the leading global provider of regulatory, clinical and compliance services for the life sciences industry, and a portfolio company of Odyssey Investment Partners, announces the expansion of its Clinical Research Solutions service with a dedicated statistical programming hub in Hyderabad, India. This strategic expansion reinforces ProPharma's commitment to improving the health and safety of patients by providing clients of all sizes with cost-efficient and 24/7/365 access to industry-leading biostatistics and programming services.
The expanded statistical programming hub in Hyderabad is designed to meet the growing demand for reliable and high-quality biostatistics support throughout the drug development lifecycle. With this expansion, ProPharma’s Biostatistics and Programming team, which is comprised of experienced professionals who specialize in a wide range of statistical methodologies and deep expertise in the life sciences industry, aims to provide its clients with enhanced capabilities to advance their development programs from conceptualization to commercialization, and through post-market stages.
Robert Rachford, ProPharma's Vice President, Biostatistics & Programming, said: "The establishment of an expanded biostatistics and programming team in our Hyderabad office marks a significant achievement for ProPharma. This milestone empowers us to deliver cost-effective and uninterrupted project coverage to our clients, while upholding our commitment to providing exceptional service that delivers quality results to advance healthcare worldwide."
ProPharma's team is committed to continuously evolving to maintain a leading-edge position to enhance and optimize its revolutionary Research Consulting Organization (RCO) model. The expanded statistical programming hub in Hyderabad features state-of-the-art infrastructure and a collaborative work environment that fosters innovation and excellence. With this investment, ProPharma is well-positioned to meet the increasing demands of the life sciences industry.
For the past 20 years, ProPharma has improved the health and wellness of patients by providing advice and expertise that empowers biotech, med device, and pharmaceutical organizations of all sizes to confidently advance scientific breakthroughs and introduce new therapies. As the world's largest RCO (Research Consulting Organization), ProPharma partners with its clients through an advise-build-operate model across the complete product lifecycle. With deep domain expertise in regulatory sciences, clinical research solutions, quality and compliance, pharmacovigilance, medical information, and R&D technology, ProPharma offers an end-to-end suite of fully customizable consulting solutions that de-risk and accelerate our partners' most high-profile drug and device programs.
For more information about ProPharma, please visit: https://www.propharmagroup.com.